Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer’s Disease

Robert Martone(Princeton University), J. Steven Jacobsen, Thomas A. Comery(Princeton University), Magid Abou‐Gharbia, S. Bradley Forlow, Scott C. Mayer, Michael W. Leach(Pfizer (United States)), Menelas N. Pangalos(AstraZeneca (United Kingdom)), Cathleen Gonzales, David Riddell(Eli Lilly (United States)), Ronald L. Magolda(Wilmington University), Xinyi Huang, Mei Jin, Erik Wagner(Princeton University), June Sonnenberg‐Reines, Jonathan Bard, Karissa Adkins, Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter H. Reinhart(University of Massachusetts Amherst), Xioahai Gong, Carrie Balliet, Hong Wan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael E. Burczynski(Teva Pharmaceuticals (United States)), Anthony F. Kreft, Shaiu-Ching Sun, Donna M. Huryn, Jane Z. Xu, David W. Clarke, Hua Zhou, Peimin Lu, Sangeeta Raje, Suzan Aschmies(Princeton University), Boyd L. Harrison, Aram Oganesian(Plex Pharmaceuticals (United States)), Glen Frick, Margaret M. Zaleska
Journal of Pharmacology and Experimental Therapeutics
August 12, 2009
Cited by 157


Related Papers